Global
中文 English

News

News

Date:2021-11-05

Subtitle: Enabling Public’s Early Access to Good Medicines


On November 6, 2021, Porton Pharma Solutions Ltd. (hereinafter referred to as Porton, stock code: 300363) and Honeywell (NASDAQ code: HON) held a Signing Ceremony of Strategic Cooperation Agreement at the 4th China International Import Expo. Porton will conduct in-depth cooperation with Honeywell in intelligent manufacturing, striving to be a world-class pharmaceutical CDMO. Yongmei (Kerry) Yu, SVP of Porton, and Chen Yan, Vice President and General Manager of Honeywell Process Control in Greater China attended this Signing Ceremony.


Signing Ceremony of Strategic Cooperation Agreement between Porton and Honeywell


According to this signed Cooperation Agreement, Honeywell will provide Porton with customized software solutions and facilities including manufacturing process control products (DCS), air conditioning automation systems (BMS/EMS), building control systems, manufacturing management systems (MES), sensors, gas monitoring systems and complete safety systems. Furthermore, the two parties will also establish in-depth cooperation in big data and machine learning so as to deepen their research and development in device interconnection and edge computing, further optimize process control, ensure the manufacturing quality and repeatability while improving the manufacturing flexibility. All these are of great help for Porton to minimize regulatory risks, improve operational efficiency and finally shorten the delivery cycles.


Yongmei (Kerry) Yu, SVP of Porton, and Chen Yan, Vice President and General Manager of Honeywell Process Control in Greater China, sign the agreement


According to this signed Cooperation Agreement, Honeywell will provide Porton with customized software solutions and facilities including manufacturing process control products (DCS), air conditioning automation systems (BMS/EMS), building control systems, manufacturing management systems (MES), sensors, gas monitoring systems and complete safety systems. Furthermore, the two parties will also establish in-depth cooperation in big data and machine learning so as to deepen their research and development in device interconnection and edge computing, further optimize process control, ensure the manufacturing quality and repeatability while improving the manufacturing flexibility. All these are of great help for Porton to minimize regulatory risks, improve operational efficiency and finally shorten the delivery cycles.


"With the advancement of information technology, the pharmaceutical industry is experiencing an important stage of digitization and intellectualization transformation. Porton is capable of delivering higher quality products at a faster pace and providing assistance in customers' drug development with its improved manufacturing automation through the intelligent manufacturing technologies and management systems. This will also create opportunities for cooperation between Porton and Honeywell," Yongmei (Kerry) Yu, SVP of Porton, said "We hope to further expand the cooperation with Honeywell, make deep communication about the digital technology continuously and work together to build the digital ecology for the pharmaceutical industry in China."


Chen Yan, Vice President and General Manager of Honeywell Process Control in Greater China, also expressed his anticipation for this cooperation. "Digital technology has become a driving factor for the pharmaceutical industry in China to accelerate its transformation and upgrading" he said, "We are very pleased to establish a strategic cooperation with Porton under the help of CIIE to join hands to explore the enormous potential of digital technology in the drug manufacturing operation and management."


As a leading CDMO in China, Porton provides global pharmaceutical companies and new drug R&D organizations with contract R&D and manufacturing services throughout the life cycle ranging from pre-clinical studies to small molecule APIs, dosage forms and biologics required for marketing. Through the strenuous efforts over the past ten years, Porton has established a good reputation and maintained good delivery records in the industry, which can be attributable to the Company's leading R&D technology, platform, capabilities, perfect quality management and EHS systems. All these are inseparable parts for the Company to maintain its leading position in this competitive industry. 


Honeywell is a global pioneer in industrial automation. It provides software solutions and facilities including automation and control solutions, safety instrumented system, connected plant solutions to interconnect processes, assets and persons, which will help companies and users make better use of data in actual operations and improve their operational safety, efficiency and reliability.


Porton and Honeywell establish this strategic cooperation under the principle of "seeking mutual benefits and achieving common development with each other's complementary advantages through long-term cooperation" to seek all-round and innovative cooperation at multiple levels in broad areas. Taking advantage of the powerful spillover effect of CIIE, the two powerful parties establish a cooperation to enable Porton to gradually build a more outstanding open collaboration platform for technological innovation and service innovation, and provide world-class end-to-end CDMO services to global customers.


About Porton


Established in 2005, Porton Pharma Solutions Ltd. is a leading pharmaceutical contract development manufacture organization (CDMO) in China. It provides global pharmaceutical companies and new drug R&D organizations with contract R&D and manufacturing services throughout the life cycle ranging from pre-clinical studies to small molecule APIs, dosage forms and biologics required for marketing. Porton has more than 3,600 employees worldwide and branch offices in China (Chongqing, Chengdu, Shanghai, Yichun, Yingcheng, Suzhou, Hong Kong), USA, Belgium, Switzerland and UK.


Porton has obtained NMPA, FDA, PMDA, EMA and WHO authoritative certifications, and is maintaining a long-term relationship with pharmaceutical giants and top drug R&D organizations around the world. Porton contributed to the development of many drugs for major diseases, such as AIDs, hepatitis, diabetes, tumours, pain, heart failure, hyperlipidemia, insomnia, epilepsy, influenza, and hypersensitivity. Some of them even reached $1 billion in annual sales.


About Honeywell


Honeywell is a Fortune Global 500 high-tech company that globally provides industry-tailored aerospace products and services, building industrial control solutions, and performance materials. It is committed to helping aircraft, buildings, plants, supply chains and workers become more connected and to make the world smarter, safer, and more sustainable. Honeywell was founded in 1885, and its long history in China goes back to 1935 when it established its first franchise in Shanghai. Seeking for a long-term development in China, Honeywell adopts the strategy of "developing and innovating products in China to service for the Chinese and global customers" to boost its growth through innovation in China. Today, all Honeywell's four Strategic Business Groups have settled in China, with its Asia-Pacific headquarters in Shanghai.

SHARE :

Back

Previous Next

Legal Notices About Porton Investor Relations

Fangzheng Avenue, Shuitu, Beibei District, Chongqing, China.

Copyright © 2020 Porton Group. DIGITAL BY VTHINK

渝ICP备11005917号-1

渝公网安备 50010902001378号